CMPXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases...

Stats
本日の出来高	65 665.00
平均出来高	375 306
時価総額	184.85M
EPS	$0 ( 2024-03-20 )
次の収益日	( $0 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.39
ATR14	$0.0120 (0.83%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-08	Boylan James P	Buy	40 000	Stock Option (Right to Buy)
2024-02-09	Gray Mary Ann	Buy	40 000	Stock Option (Right to Buy)
2024-02-09	Lindahl Richard S	Buy	40 000	Stock Option (Right to Buy)
2024-02-09	Gordon Carl L	Buy	40 000	Stock Option (Right to Buy)
2024-02-09	Chiniara Ellen	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
93.94
Last 94 transactions
Buy: 28 287 388 \| Sell: 226 920

ボリューム相関

長: 0.04 (neutral)

短: 0.05 (neutral)

Signal:(49.093) Neutral

Compass Therapeutics, 相関

10 最も正の相関
PIXY	0.935
WTBA	0.915
UPC	0.91
LLNW	0.909
GSMG	0.908
ALXO	0.905
ENNV	0.902
YJ	0.902
BMRA	0.897
LVTX	0.893

10 最も負の相関
HHGC	-0.937
KYCH	-0.936
UONE	-0.936
OLED	-0.931
PPD	-0.93
SIBN	-0.927
CDNS	-0.927
NVTS	-0.923
ALYA	-0.923
MELI	-0.923

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Compass Therapeutics, 相関 - 通貨/商品

-0.60
( weak negative )

-0.36
( neutral )

0.00
( neutral )

-0.46
( neutral )

0.00
( neutral )

0.41
( neutral )

Compass Therapeutics, 財務諸表

Annual	2022
収益:	$0
総利益:	$-1.90M (0.00 %)
EPS:	$-0.350

FY	2022
収益:	$0
総利益:	$-1.90M (0.00 %)
EPS:	$-0.350

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.583

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.566

Financial Reports:

No articles found.

Compass Therapeutics,

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

リアルタイムの更新： Compass Therapeutics, [CMPX]

Upcoming Earnings Alert